FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader:Investec Bank plc(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereePRS Reit PLC(c) Name of the party to the offer with which exempt principal trader is connected:Investec is Adviser t ...

Rotterdam, The Netherlands (22 October 2025) We are pleased to inform you that IMCD will publish its First Nine Months 2025 results on Thursday 6 November 2025 at 07.00 am CET. Following the publication, Marcus Jordan (CEO) and Hans Kooijmans (CFO) will host an analyst conference call & webcast starting at 09.00 am CET. The presentation will be made available on the publication date at 7:00 am CET on our website under the Investor Relations section. A replay of the webcast will be uploaded to our website s ...

22 October 2025 LEI: 2138003QW2ZAYZODBU23 LSE Code: 3SIS WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY(a public company incorporated with limited liability in Ireland)WISDOMTREE SILVER 3X DAILY SHORT SECURITIES ISIN: IE00B8JG1787 PROPOSED AMENDMENT TO THE PRINCIPAL AMOUNT OF THE AFFECTED SECURITIES MEETING OF THE ETP SECURITYHOLDERS THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about what action you should take, you are recommended to consult your independe ...

Core Insights - The company reported core earnings of DKK 2,321 million and a net profit of DKK 1,753 million for the first three quarters of 2025, reflecting a 21% p.a. return on equity [2][4] Financial Performance - Total core income for Q1-Q3 2025 was DKK 3,073 million, slightly higher than DKK 3,067 million in the same period of 2024 [3][4] - Total expenses and depreciation increased to DKK 787 million from DKK 761 million in 2024, marking a 4% rise [3][4] - Core earnings before impairment charges were DKK 2,286 million, compared to DKK 2,306 million in 2024 [3] - Impairment charges for loans were DKK 35 million for the first three quarters of 2025, indicating strong credit quality [4] Earnings Metrics - Earnings per share increased by 4% to DKK 71.2 for the first three quarters of 2025 [4] - The cost/income ratio stood at 25.6%, reflecting the increase in costs relative to income [4] Customer and Loan Growth - The company experienced a 7% p.a. growth in loans and a 9% p.a. growth in deposits, alongside a satisfactory increase in customer numbers [4]

Core Viewpoint - Solar Norge AS has signed an agreement to acquire 100% of Sonepar Norge AS for an enterprise value of DKK 315 million, with the transaction expected to enhance operational and commercial synergies, driving growth and earnings in the Norwegian market [1][2][5] Transaction Overview - The acquisition will be financed through a combination of 1/3 equity financing and 2/3 debt financing, with expected acquisition costs of DKK 5 million in 2025 [1][6] - The transaction is subject to regulatory approvals and is anticipated to be completed by early December 2025 [6][8] Strategic and Financial Rationale - The combination of Solar and Sonepar is seen as a unique opportunity to create a leading distributor in Norway, focusing on electrical, ventilation, climate, and energy solutions [5][6] - The acquisition is expected to generate a combined annual revenue of approximately DKK 2.5 billion and a portfolio of 25,000 stock keeping units (SKUs) [3][6] Company and Market Position - Sonepar Norge has a strong market presence with an annual revenue of approximately DKK 700 million, a loyal customer base of nearly 4,000, and a comprehensive portfolio of over 12,000 SKUs [2][3] - The integration of operations is expected to yield significant operational synergies, including consolidation of administration, logistics, and IT infrastructure [7][8] Sustainability Focus - Both companies emphasize sustainability, with Sonepar focusing on ESG-compliant sourcing, which aligns with Solar's commitment to driving the green transition [2][10]

Core Points - SNCF Voyageurs has approved an order for 30 new-generation Avelia Horizon very high-speed trains for approximately €1.4 billion, with options for 20 additional trains, scheduled for delivery in 2031 [1][10] - The Avelia Horizon trains will operate under the Eurostar brand across five countries, including Germany, Belgium, France, the Netherlands, and the UK, marking the first use of a double-deck high-speed train through the Channel Tunnel [2][10] - Alstom's Avelia Horizon trains are designed for international very high-speed traffic, emphasizing technological performance, energy efficiency, and passenger comfort [3][5] Train Specifications - The Avelia Horizon can reach speeds over 300 km/h and has a capacity of over 1,000 passengers, featuring nine articulated double-deck cars and two compact power cars [6][8] - The new train consumes 20% less energy than its predecessor due to advanced aerodynamic design and optimized traction [6] - Maintenance costs have been reduced by 30% compared to the previous generation, with predictive maintenance integrated into the design [7] Production and Employment - Alstom is investing €150 million to increase production capacity at ten of its French sites to meet growing demand for the Avelia trains [10] - The Avelia Horizon program involves collaboration across ten national sites in France, showcasing the country's rail expertise [9] Market Presence - Alstom's Avelia range includes trains with maximum speeds between 200 km/h and 350 km/h, with over 1,000 Avelia trains operating in 25 countries [12]

Quarterly information report as at the end of September 2025 Continued solid sales growth in the third quarter(+10% at constant exchange rates and +5% at current exchange rates) Paris, 22 October 2025 In the third quarter, sales continued to grow and reached €3.9 billion, up 10% at constant exchange rates, a slight improvement compared to the second quarter, particularly in Europe, the Americas and Asia. The group’s consolidated revenue amounted to €11.9 billion at the end of September 2025, up 9% at const ...

Core Financial Performance - The bank reported core earnings of DKK 2,321 million and a net profit of DKK 1,753 million for the first three quarters of 2025, reflecting a 21% annual return on equity [1][4] - Total core income for the first three quarters of 2025 was DKK 3,073 million, slightly higher than the same period in 2024 [4] - Earnings per share increased by 4% to DKK 71.2 for the first three quarters of 2025 [4] Expense Management - Total expenses and depreciation amounted to DKK 534 million, a decrease from DKK 761 million in the same period of 2024 [2] - The cost/income ratio improved to 25.6%, indicating effective cost management despite a 4% increase in costs [4] Credit Quality and Impairment Charges - The bank maintained strong credit quality, with impairment charges of DKK 11 million recorded in the quarter, leading to total impairment charges of DKK 35 million for the first three quarters of 2025 [4] - Impairment charges for loans showed a positive trend, with a charge of +24 million in the first three quarters of 2025 compared to +2 million in 2024 [2] Customer Growth and Loan/Deposit Trends - The bank experienced a satisfactory increase in customer numbers, with loans growing at a rate of 7% per annum and deposits at 9% per annum [4]

Core Points - Sampo plc has conducted a share buyback on 21 October 2025, acquiring a total of 351,896 A shares at an average price of EUR 9.66 per share [1][2] - The share buyback program, announced on 6 August 2025, has a maximum limit of EUR 200 million and is in compliance with the Market Abuse Regulation [1] - Following the transactions, Sampo plc now holds a total of 18,131,091 A shares, which represents 0.67% of the total shares outstanding [2] Summary by Sections Share Buyback Details - On 21 October 2025, Sampo plc acquired 351,896 A shares across various markets, with the daily weighted average price being EUR 9.66 [1] - The buyback was executed on multiple exchanges, including AQEU, CEUX, TQEX, and XHEL [1] Program Announcement - The share buyback program was initiated on 7 August 2025, following authorization from Sampo's Annual General Meeting held on 23 April 2025 [1] - The program aims to utilize up to EUR 200 million for the buyback of shares [1] Ownership Post-Transaction - After the buyback transactions, Sampo plc's total ownership of A shares stands at 18,131,091, equating to 0.67% of the total shares [2]

Core Insights - Novartis announced that Cosentyx® (secukinumab) achieved significant results in the Phase III REPLENISH trial for treating polymyalgia rheumatica (PMR), meeting both primary and secondary endpoints [1][7] - The trial demonstrated that Cosentyx provided sustained remission compared to placebo at Week 52, indicating its potential as a novel treatment option for PMR [1][7] Company Overview - Novartis is an innovative medicines company focused on improving and extending patients' lives through advanced therapies, reaching nearly 300 million people globally [9] Product Information - Cosentyx is a fully human biologic that inhibits interleukin-17A, a key cytokine in various immune-mediated inflammatory diseases, and is already approved for multiple conditions including psoriatic arthritis and ankylosing spondylitis [4] - Since its launch in 2015, Cosentyx has treated over 1.8 million patients worldwide and is approved in more than 100 countries [4] Clinical Trial Details - The REPLENISH trial was a global Phase III, multicenter, randomized, double-blind, placebo-controlled study conducted in 27 countries, assessing the efficacy and safety of Cosentyx in PMR patients [3] - The primary endpoint was to determine if secukinumab 300mg plus a steroid taper was superior to placebo plus a steroid taper in achieving sustained remission at Week 52 [3] Disease Context - Polymyalgia rheumatica is the second most common inflammatory rheumatic disease in adults aged 50 and older, characterized by significant pain and stiffness, which can severely impact quality of life [5] - Long-term steroid use, the standard treatment, poses risks such as osteoporosis and diabetes, highlighting the need for effective alternatives like Cosentyx [5]